Y-mabs and the european medicines agency reach agreement on the pediatric investigation plan for naxitamab

New york, feb. 02, 2023 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the european medicines agency (“ema”) has agreed to the company's proposed pediatric investigation plan (“pip”) for naxitamab. the decision follows a positive opinion from ema's pediatric committee (“pdco”). naxitamab is being developed by y-mabs for the treatment of patients with relapsed/refractory high-risk neuroblastoma, which is the indication targeted by the pip, as well as osteosarcoma.
YMAB Ratings Summary
YMAB Quant Ranking